Rule 8 - Cambridge Antibody
February 27 2003 - 8:00AM
UK Regulatory
RNS Number:0684I
ISIS Asset Management PLC
27 February 2003
Date of Disclosure 27TH FEBRUARY 2003
DISCLOSURE UNDER RULES 8.1(a), 8.1(b)(i) and 8.3
OF THE CITY CODE ON TAKEOVERS AND MERGERS
Date of dealing 26TH FEBRUARY 2003
Dealing in CAMBRIDGE ANTIBODY TECHNOLOGY (name of company)
1) Class of securities (eg ordinary shares) ORDINARY 10P SHARES
2) Amount bought Amount sold Price per unit
12,201 4.300
497 4.300
2,302 4.300
3) Resultant total of the same class owned or controlled
(and percentage of class) 402,762 (1.11%)
4) Party making disclosure ISIS ASSET MANAGEMENT PLC
5) EITHER (a) Name of purchaser/vendor (Note 1)
OR (b) if dealing for discretionary client(s), name of fund
management organisation ISIS ASSET MANAGEMENT PLC
6) Reason for disclosure (Note 2)
(a) associate of (i) offeror (Note 3) NO
(ii) offeree company NO
Specify which category or categories of associate (1-8 overleaf) 6
If category (8), explain
(b) Rule 8.3 (ie disclosure because of ownership or control of 1%
or more of the class of relevant securities dealt in) YES
Signed, for and on behalf of the party named in (4) above N/A
(Also print name of signatory) DOUGLAS STEWART
Telephone and extension number 0131 465 1092 JENNIFER URQUHART
Note 1. Specify owner, not nominee or vehicle company. If relevant, also
identify controller of owner, eg where an owner normally acts on
instructions of a controller
Note 2. Disclosure might be made for more than one reason; if so, state all
reasons.
Note 3. Specify which offeror if there is more than one.
Note 4. When an arrangement exists with any offeror, with the offeree company
or which an associate of any offeror or of the offeree company
in relation to relevant securities, details of such arrangement must
be disclosed, as required by Note 6 on Rule 8
Note 5. It may be necessary, particularly when disclosing derivative
transactions, to append a sheet to this disclosure form so that
relevant information can be given.
Note 6. In the case of an average price bargain, each underlying trade
should be disclosed.
For full details of disclosure requirements, see Rule 8 of the Code. If in
doubt, contact the Panel on Takeovers and Mergers, Tel No: 020 7382 9026
This information is provided by RNS
The company news service from the London Stock Exchange
END
DCCUBRURORRUUAR